Interleukin-31 new biomarker of infectious skin diseases
Introduction. The introduction of antiretroviral therapy has significantly improved the long-term prognosis of AIDS patients, but opportunistic infections can still be life-threatening for this population. Among them, a large group constitutes of herpesvirus infections, which are frequent manifest forms of dermatological manifestations of HIV. The researching of IL-31, as a prospective diagnostic predictor of dermatological diseases, has been actively conducted in recent years. This is due to the interest in its biological action, which extends primarily to the skin. Тhe identification of molecular targets underlying inflammatory and infectious dermatoses is promisingly for the development of new, targeted treatments. Objective: to study the role of IL-31 in the immunopathogenesis of herpesvirus infections associated with HIV infection. Research objectives: 1) to compare the levels of IL-31 in the blood serum in patients with herpesvirus skin diseases associated with HIV infection and in healthy subjects; 2) to determine the presence of a relationship between the levels of IL-31 in the blood serum and the clinical stage of the disease. Materials and methods. The study included patients with herpesvirus infection caused by HSV-1, HSV-2, VZV-3, EBV and HHV-8 associated with HIV infection and healthy individuals. Serum IL-31 levels were measured by ELISA using commercial kits (Human IL-31 ELISA Kit, Abcam, Cambridge, MA, USA). Were collected the baseline clinical characteristics, assessment of the activity of the infectious process and the degree of immunosuppression. Results. Our study involved 39 patients with herpesvirus infection associated HIV and 31 patients of the control group. In patients with herpesvirus infection against the background of HIV infection, the average level of IL-31 in the blood serum was significantly higher than that of healthy subjects. Serum IL-31 levels in patients with herpesvirus infection did not differ significantly depending on the severity of the process and the degree of immunosuppression. Conclusion. The levels of IL-31 in the blood serum of patients with herpesvirus infection were differed by statistically significant validity in comparison with similar indicators of healthy individuals, which confirms its role in the pathogenesis of infectious skin diseases.
Mirnezami М., Zarinfar N., Sofian М., Yadegar B. B., Rahimi H. Manifestations in HIV-Infected Patients and Their Relationship to CD4 Lymphocyte Counts. J Scientifica (Cairo). 2020; Aug 11: 7503756. https://doi.org/10.1155/2020/7503756
Sarah J. C., Kieron S. L. What's new in HIV dermatology? Version 1. F1000Res. 2019;.8:.886. https://doi.org/10.12688/f1000research.16182.1.
Liadova T. I., Popov M. M., Dorosh D. M., Martynenko A. V., Volobueva O. V., Kadyhrob I. V., Sorokina O. G., Gamilovskaya A. P., Gololobova O. V., Shepylieva N. V. Assessment of immunological effects of melatonin in immunodeficient population: a systematic review of 180190 randomized controlled trials. J Lekarsky Obzor. 2021; 1: 25–32. ISSN: 04574214
Stashkevich D. S. (2016). Topical issues of immunology: the cytokine system, biological significance, genetic polymorphism, methods of determination: textbook. manual [Text] / D. S. Stashkevich, Yu. Yu. Filippova, A. L. Burmistrova. – Chelyabinsk: Tsitsero. – 82 p. Chelyabinsk Tsitsero, 8–15.
Dillon S. R., Sprecher C., Hammond A., Bilsborough J., Presnell S. R., Haugen H. S., Maurer M., Harder B., Johnston J., Bort S., Mudri S., Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. J. Nat Immunol. 2004. Jul; 5 (7): 752–60. https://doi.org/10.1038/ni1084.
Hermanns H. M. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. J. Cytokine Growth Factor Rev. 2015; Oct; 26 (5): 545–58. https://doi.org/10.1016/j.cytogfr.2015.07.006.
Kasraie S., Niebuhr M., Werfel T. Interleukin (IL)-31 inducespro-inﬂammatory cytokines in human monocytes and macrophagesfollowing stimulation with staphylococcal exotoxins. J. Allergy. 2010; 65: 712–721. https://doi.org/10.1111/j.1398-9995.2009.02255.x.
Cornelissen C., Marquardt Y., Czaja K., Wenzel J. et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012; Feb; 129 (2): 426–33, 433.e1-8. https://doi.org/10.1016/j.jaci.2011.10.042. Epub 2011 Dec 15.
Abbas F. M. Alkarkhi, Wasin A. A. Alqaraghuli. Discriminant Analysis and Classification, Easy Statistics for Science with R, Ch. 10, Academic Press, 2019, p. 161–175, https://doi.org/10.1016/B978-0-12-814262-2.00010-8
Pérez N., López M., Silva A., Ramos I. Improving the Mann–Whitney statistical test for feature selection: An approach in breast cancer diagnosis on mammography. Artificial Intelligence in Medicine,Vol. 63, Iss. 1, 2015, p. 19–31, https://doi.org/10.1016/j.artmed.2014.12.004.
Gibbs B. F., Patsinakidis N., Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases, Front. Immunol. 2019; 10: 1383. https://doi.org/10.3389/fimmu.2019.01383
Neis M. M., Peters B., Dreuw A., Wenzel J., Bieber T., Mauch C. et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis, J. Allergy Clin. Immunol. 2006; 118 (4): 930–937. https://doi.org/10.1016/j.jaci.2006.07.015.
Narbutt J., Olejniczak I., Sobolewska-Sztychny D. et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients, Arch. Dermatol. Res. 2013; 305 (3): 191–195. https://doi.org/10.1007/s00403-012-1293-6
Bilsborough J., Leung D. Y., Maurer M. et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis, J. Allergy Clin. Immunol. 2006; 117 (2): 418–425. https://doi.org/10.1016/j.jaci.2005.10.046.
Salao K., Sawanyawisuth K., Winaikosol K. et al. Interleukin-31 and chronic pruritus of unknown origin. Biomark Insights. 2020; 15, 1177271920940712. https://doi.org/10.1177/1177271920940712.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.